New report finds that Trikafta patients’ admissions to hospital fell by an average of 65 per cent over one year – but at a ...

Rena Barrow has two sons with cystic fibrosis, born 20 years apart — but they faced the same terrible delay in diagnosis.

The change comes in light of a recommendation made earlier this month by the Canadian Agency for Drugs and Technologies in ...

More cystic fibrosis (CF) patients in Saskatchewan now have access to Trikafta, a groundbreaking medication that improves lung function and quality of life. As of November 15, the province has ...

Arcturus Therapeutics expects interim results for LUNAR-CF and LUNAR-OTC in 2025. Learn why ARCT stock presents an ...

The Saskatchewan government has announced it is increasing coverage for a drug used to treat cystic fibrosis. Patients and ...

The provincial government announced Monday that more cystic fibrosis (CF) patients in Saskatchewan are now eligible for ...

The firm's chief scientific officer called the achievement "a major milestone for Spirovant and for the cystic fibrosis ...

The company’s approved cystic fibrosis drugs include Kalydeco, Symdeko and Trikafta. Vertex’s pipeline also includes non-cystic fibrosis treatment candidates, including exa-cel for beta ...

"We envisage that this method of drug delivery can also be used to treat other lung conditions such as cystic fibrosis, infections and pulmonary emphysema. In other words, methods other than ...

and others are evaluating new non-cystic fibrosis bronchiectasis drugs to improve the treatment landscape. Promising pipeline non-cystic fibrosis bronchiectasis therapies such as Colistimethate sodium ...